Abbott’s m-PIMA HIV-1/2 VL, the world’s first point-of-care viral load diagnostic test, has received the World Health Organization’s Prequalification approval. The test received CE Mark in December 2018. Viral load testing is the gold standard for monitoring ART treatment failure.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.